Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Escudier

Showing results (81-90 of 362) with videos related to

Pageof 37
Sort By:
Oncoimmunology|May 8, 2015
HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysisYosra Messai, Muhammad Zaeem Noman, Meriem Hasmim, et al.
Clinical Genitourinary Cancer|November 14, 2013
Considerations for the design of future clinical trials in metastatic renal cell carcinomaBernard Escudier, Daniel Y C Heng, Arthur Smyth-Medina, et al.
Urologic Oncology|August 23, 2015
Interleukin-6 as an emerging regulator of renal cell cancerKatarzyna Kamińska, Anna M Czarnecka, Bernard Escudier, et al.
Cancer Treatment Reviews|September 25, 2016
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapyEmiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, et al.
Angiogenesis|February 11, 2019
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validationLisa Derosa, Mohamed Amine Bayar, Laurence Albiges, et al.
European Urology Focus|July 21, 2017
Immunotherapy for Renal Cancer: Sequencing and CombinationsGrant D Stewart, Maria De Santis, Bernard Escudier, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2008
Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patientsEmilie Viey, Claire Lucas, François Romagne, et al.
Clinical Genitourinary Cancer|September 1, 2022
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World StudyBernard Escudier, Marie de Zélicourt, Redha Bourouina, et al.
European Urology|February 26, 2003
A 10-year clinical experience with intermittent hormonal therapy for prostate cancerDominique Prapotnich, Karim Fizazi, Bernard Escudier, et al.
Expert Opinion on Drug Safety|May 5, 2016
Safety of available treatment options for renal cell carcinomaLisa Derosa, Laurence Albiges, Christophe Massard, et al.
Pageof 37

Showing results (81-90 of 362) with videos related to

Sort By:
Pageof 37
Oncoimmunology|May 8, 2015
HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysisYosra Messai, Muhammad Zaeem Noman, Meriem Hasmim, et al.
Clinical Genitourinary Cancer|November 14, 2013
Considerations for the design of future clinical trials in metastatic renal cell carcinomaBernard Escudier, Daniel Y C Heng, Arthur Smyth-Medina, et al.
Urologic Oncology|August 23, 2015
Interleukin-6 as an emerging regulator of renal cell cancerKatarzyna Kamińska, Anna M Czarnecka, Bernard Escudier, et al.
Cancer Treatment Reviews|September 25, 2016
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapyEmiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, et al.
Angiogenesis|February 11, 2019
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validationLisa Derosa, Mohamed Amine Bayar, Laurence Albiges, et al.
European Urology Focus|July 21, 2017
Immunotherapy for Renal Cancer: Sequencing and CombinationsGrant D Stewart, Maria De Santis, Bernard Escudier, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2008
Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patientsEmilie Viey, Claire Lucas, François Romagne, et al.
Clinical Genitourinary Cancer|September 1, 2022
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World StudyBernard Escudier, Marie de Zélicourt, Redha Bourouina, et al.
European Urology|February 26, 2003
A 10-year clinical experience with intermittent hormonal therapy for prostate cancerDominique Prapotnich, Karim Fizazi, Bernard Escudier, et al.
Expert Opinion on Drug Safety|May 5, 2016
Safety of available treatment options for renal cell carcinomaLisa Derosa, Laurence Albiges, Christophe Massard, et al.
Pageof 37